Ambitious biotech fund shuts down before first investment

Sund Capital aimed high when the investment fund, led by former Zealand Pharma CEO David Solomon, announced its ambition of raising up to DKK 2 billion for investing in promising biotech companies. Now, the fund is shutting down.

Photo: /ritzau scanpix/Søren Bidstrup

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles